

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC20170005992				
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)				
Palabras clave utilizadas		TRIAZOLOPYRIMIDINE; POLYCOMB; REPRESSIVE; COMPLEX 2; CANCER.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07D 487/04, A61K 31/519, A61P 35/00.		
		CPC (Opcional):		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
ORBIT, EPOQUENET, ESPACENET, USPTO Y PATBASE	WO03044021	30/05/2003	No afecta	A
	WO2014144747	18/09/2014	No afecta	A
	EP1273666	04/07/2001	No afecta	A
	WO2016103155	30/06/2016	Solicitud	--
** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	
Fecha del reporte de búsqueda:	01/08/2018

ESPACENET

Cited in	International search	[A]➤ WO03044021 (AMGEN INC [US], et al) [A] 1-20 * claims 1 and 30. Table 5 *;
		[A]➤ WO2014144747 (EPIZYME INC [US]) [A] 1-20 * claim 1 and page 1 *
	by applicant	→ WO2004078163

USPTO

Patent eBusiness

Electronic Filing

Patent Application Information (FAQs)

Patent Ownership

Fees

Supplemental Resources & Support

Patent Information

Patent Guidance and General Info

Codes, Rules & Manuals

Employee & Office Directories

Resources & Public Notices

Patent Searches

Patent Official Gazette

Search Patents & Applications

Search Biological Sequences

Copies, Products & Services

Other

Copyrights

Trademarks

Policy & Law Reports

Patent Application Information Retrieval

Global Dossier

Order Certified Application As Filed

Order Certified File Wrapper

View Order List

14/977,273

TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

PAT056471-US-NP

Select New Case

Application Data

Transaction History

Image File Wrapper

Patent Term Adjustments

Foreign Priority

Fees

Published Documents

Address & Attorney/Agent

Assignments

Display References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Patent Information	Document Code	Document Description	Document Category	Page Count		
Patent Guidance and General Info Codes, Rules & Manuals Employee & Office Directories Resources & Public Notices Patent Searches Patent Official Gazette Search Patents & Applications Search Biological Sequences Copies, Products & Services Other Copyrights Trademarks Policy & Law Reports	Mail Room Date 12-26-2017	Document Code COCOUT	Document Description Certificate of Correction - Post Issue Communication	Document Category PROSECUTION	Page Count 2	☐
	12-06-2017	COCX	SPE Response - Certificate of Correction under 1.323/1.324	PROSECUTION	2	☐
	10-05-2017	COCIN	Request for Certificate of Correction	PROSECUTION	2	☐
	10-05-2017	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
	02-08-2017	ISSUE.NTF	Issue Notification	PROSECUTION	1	☐
	01-19-2017	PET.DEC.OIPE	Petition decision routed to the OIPE to act on the decision or continue prosecution.	PROSECUTION	2	☐
	12-20-2016	M327	Miscellaneous Communication to Applicant - No Action Count	PROSECUTION	1	☐
	12-20-2016	IFEE	Issue Fee Payment (PTO-85B)	PROSECUTION	1	☐
	12-20-2016	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
	12-20-2016	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
	12-13-2016	PET.OP	Petition for review by the Office of Petitions	PROSECUTION	2	☐
	12-13-2016	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐

Easy search

Save strategy

Menu

Filter

Explorer

4 results for 12 AND (TRIAZOLOPYRIMIDINE) - Collection: FAMPAT

Select

1

2

3

4

Title

Dna sequences having anti-repressor activity

2 Triazolopyrimidine compounds and uses thereof

3 Crystalline forms of triazolopyrimidine compound

4 Triazolopyrimidine compounds and uses thereof

Publication number

EP1273000

US20160176882

WO2017219948

IN4248/DEL/2015

1st app. date

2001-07-04

2015-12-21

2017-06-19

2015-12-23

Applicant/Assignee

CHROMA GENI...

NOVARTIS*

NOVARTIS*

NOVARTIS*

Relevance

100 %

75 %

61 %

45 %

Litigation

Display

1

2

3

4

Preview

Image

Translate

Edit

Dna sequences having anti-repressor activity

1

2

3

4

STAR

levA operators

oriP

EBNA-1

amp^R

ori

SV40-PA

Resistance Marker (Zeocin, Puromycin) or Reporter (Luciferase, GFP)

SV40 Promoter

cloning site (BamHI, XbaI, SalI, KpnI, HindIII)

pSelect

EPOQUENET



New connection on: : 03-08-2018 : 01:03:30 - Last disconnection on: :
02-08-2018 : 21:46:34

V 4.0.0.44258(15, Linux) (Rev03856 2017-04-27 09:02:29 +0100)(0201802) (RPM 0201802)

Welcome to EPOQUE Rebuild under the Production Environment

[EPODOC: SS 1] --II

Results in EPODOC 0

EPODOC: term "--II" not found in index 'Bf'. WARNING(1)

[SS 2] ..fi

Select a database: ..fi EPODOC

☐ Database: EPODOC

[EPODOC: SS 2] TRIAZOLOPYRIMIDINE AND POLYCOMB AND REPRESSIVE AND COMPLEX AND "2" AND
CANCER.

Results in EPODOC 0

EPODOC: term 'CANCER.' not found in index 'Bf'. WARNING(1)

[SS 3] TRIAZOLOPYRIMIDINE AND POLYCOMB AND REPRESSIVE AND COMPLEX

Results in EPODOC 0

[SS 4] PRC2 AND TRIAZOLOPYRIMIDINE

Results in EPODOC 9

[SS 5] 4 AND CANCER

Results in EPODOC 0

[SS 6] 4 AND SARCOMA

Results in EPODOC 0

[SS 7] PRC2 AND TRIAZOLOPYRIMIDINE

Results in EPODOC 9

1/9 © EPODOC / EPO

PN - WO2017219948 A1 20171228

TI - CRYSTALLINE FORMS OF TRIAZOLOPYRIMIDINE COMPOUND


AB - Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

2/9 © EPODOC / EPO


PN - PH12017501016_A1 20171211

T1 - TRIAZOLOPYRIMIDINE
COMPOUNDS AND USES THEREOF

AB - A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.




- PN - [CN107108637](#), A 20170829
- TI - Triazolopyrimidine compounds and uses thereof
- AB - A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R¹, R², R³, R⁴, R⁵, and n are as defined herein.




(I)

- 6/9 © EPODOC / EPO
- PN - [AU2015370524](#), A1 20170601
- TI - Triazolopyrimidine compounds and uses thereof
- AB - A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R




(I)

- 7/9 © EPODOC / EPO
- PN - [TW201629065](#), A 20160816
- TI - Triazolopyrimidine compounds and uses thereof
- AB - A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R¹, R², R³, R⁴, R⁵, and n are as defined herein.



(I)

- 8/9 © EPODOC / EPO
- PN - [US2016176882](#), A1 20160623
- TI - (A1)
TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
- (B2)
Triazolopyrimidine compounds and uses thereof
- AB - (A1)
A compound of Formula (I), or a pharmaceutically acceptable salt



(I)


thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

9/9 © EPODOC / EPO

PN - [WO2016103155_A1](#) 20160630

TI - TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

AB - A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.



(I)